Paliperidone Palmitate Launch Unlikely Until 2010, J&J Says
This article was originally published in The Pink Sheet Daily
Executive Summary
New dosing option for the atypical antipsychotic will be included in the NDA resubmission.
You may also be interested in...
J&J Advances Pipeline With Yondelis, Carisbamate Filings
Johnson & Johnson progressed its pipeline with the filing of two novel drugs late in 2008: trabectedin (marketed outside the U.S. as Yondelis) for the treatment of relapsed ovarian cancer, and carisbamate for the adjunctive treatment of partial onset seizures
J&J Advances Pipeline With Yondelis, Carisbamate Filings
Johnson & Johnson progressed its pipeline with the filing of two novel drugs late in 2008: trabectedin (marketed outside the U.S. as Yondelis) for the treatment of relapsed ovarian cancer, and carisbamate for the adjunctive treatment of partial onset seizures
Johnson & Johnson Push Ahead With Invega Franchise
Firm files response to “complete response” letter for once-monthly version and tries for new indication for once-daily paliperidone.